Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.

Myovant saw positive results in the first of two Phase III studies of a combination therapy for pain associated with endometriosis. The Switzerland-based company said the SPIRIT-2 study met the co-primary efficacy endpoints and six key secondary endpoints.

Switzerland-based Myovant announced an 88 percent one-year response rate in the positive Phase III LIBERTY extension study of once-daily, oral relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids.

Shares of AbbVie were up after the FDA granted regulatory approval for the company’s endometriosis drug Orilissa (elagolix).